China’s Healthcare Reform To Spur Vaccine Market Expansion
This article was originally published in PharmAsia News
China recently unveiled its finalized healthcare reform plan (PharmAsia News, Apr. 8, 2009), which aims to make basic healthcare accessible for all its citizens in both urban and rural areas. The prevention-oriented reform will bring huge market opportunities for vaccine manufacturers. According to estimates, China's public healthcare expenditure will reach RMB 19.5 billion ($2.85 billion) in 2009, and RMB 26 billion ($3.8 billion) by 2011. At this growth rate, the vaccine sector is expected to increase more than 30 percent. With per capita healthcare expenditure rising, the nation will prioritize the usage of vaccines and pay for its application. As China's leading vaccine producer, Sinovac said it will benefit from the reform and is putting its focus to cater more to public interest. (Click here for more - Chinese language)
You may also be interested in...
SHANGHAI - China issued its long-awaited three-year plan for its healthcare reform, and unveiled how the country will allocate RMB 850 billion ($124 billion) in the next three years
A selective androgen receptor modulator also being studied in metastatic breast cancer, enobosarm might offer potential as add-on therapy to GLP-1 agonists prescribed for weight loss, the Miami biotech asserts.
In this episode, Medtech Insight regulatory reporter Hannah Daniel speaks to Washington Analysis vice president and senior healthcare analyst John Leppard about the Center for Medicare and Medicaid’s Transitional Coverage Of Emerging Technologies pathway, or TCET. He breaks down the pathway and discusses its pros and cons, as well as potential next steps for the agency. We also explore the history of breakthrough device coverage as well as the challenges for coverage of digital health devices.